Q1 Earnings Forecast for TSE:GUD Issued By Stifel Canada

Knight Therapeutics Inc. (TSE:GUD) – Equities research analysts at Stifel Canada issued their Q1 2025 earnings per share estimates for Knight Therapeutics in a research report issued on Monday, March 24th. Stifel Canada analyst J. Keywood anticipates that the company will earn $0.03 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics’ Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.04 EPS and FY2026 earnings at $0.21 EPS.

A number of other brokerages also recently issued reports on GUD. Canaccord Genuity Group downgraded shares of Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, March 21st. Stifel Nicolaus raised their target price on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a “buy” rating in a report on Tuesday. Finally, Research Capitl upgraded shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of C$7.48.

Knight Therapeutics Price Performance

TSE GUD opened at C$6.09 on Thursday. Knight Therapeutics has a one year low of C$5.09 and a one year high of C$6.45. The stock has a 50-day moving average of C$5.74 and a 200 day moving average of C$5.60. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The company has a market capitalization of C$616.00 million, a price-to-earnings ratio of -20.33, a PEG ratio of -1,013.50 and a beta of 0.50.

Insider Activity at Knight Therapeutics

In related news, insider Sime Armoyan bought 17,600 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average cost of C$5.48 per share, with a total value of C$96,488.48. Over the last ninety days, insiders sold 3,143,300 shares of company stock worth $19,733,740. 45.62% of the stock is owned by company insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.